Side-by-side · Research reference
MazdutidevsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED19/62 cited
BFDA-ApprovedFlagship14/45 cited
Mazdutide
GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3
SQ · Abdomen · Once WeeklyJi 2026
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Mazdutide
Tirzepatide
Primary target
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Yes — physiological receptor-mediated signaling preserved
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Mazdutide
Tirzepatide
Phase 2 studied dose
—
Dose escalation
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration (trials)
24–48 weeks
—
Population
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
—
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
—
Once weekly, any time of day
03Metabolic / Fat Loss Evidence
Parameter
Mazdutide
Tirzepatide
Percentage body weight loss
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
—
Responder rate (≥10% loss)
Not explicitly reported in available abstracts
—
Visceral fat
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
—
Glycemic improvement
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
—
Key publications
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
—
04Side Effects & Safety
Parameter
Mazdutide
Tirzepatide
Gastrointestinal symptoms
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
—
Injection site reactions
Erythema, pruritus, local discomfort
—
Hypoglycemia
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
Low as monotherapy; risk with sulfonylureas / insulin
Cardiovascular effects
Increased heart rate (glucagon effect, transient)
—
Pancreatitis risk
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023
Thyroid C-cell tumors
Black box warning for GLP-1 class (rodent data); human relevance unclear
—
Gallbladder disease
Cholelithiasis, cholecystitis (rapid weight loss effect)
—
Tolerability
Generally well-tolerated; GI effects diminish with dose titration
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Gallbladder events
—
Increased cholelithiasis
Pregnancy / OB
—
Contraindicated
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Mazdutide
Tirzepatide
1. Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
Pen-supplied. Research vial: 27–31G insulin syringe.